Who Paid My Doc
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis
Research payments
$1,752,500
Through program year 2025, $1,752,500 in research payments was reported against A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis, across 61 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,752,500 | 61 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Corinne Howington Savannah, GA Named on 27 payments
- Sharon Albers Tampa, FL Named on 2 payments
- Giovanna Ciocca Miami, FL Named on 2 payments
- Lara Wine Lee Charleston, SC Named on 2 payments
- Jeannette Jakus Brooklyn, NY Named on 2 payments
- Navid Ezra Thousand Oaks, CA Named on 2 payments
- Mary Moore Missouri City, TX Named on 1 payment
- Sandra Johnson Fort Smith, AR Named on 1 payment
- Scott Fretzin Indianapolis, IN Named on 1 payment
- Lauren Campbell Cypress, TX Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.